HK Stock Market Move | AKESO(09926) surged over 17% to hit a new high, with a cumulative increase of over 45% for the month. Morgan Stanley said that the Ivosi HARMONi-2 data far exceeded expectations.

AKESO (09926) surged by over 17% during trading, reaching a high of HKD 72.55, setting a new historical high. The stock has accumulated a gain of over 45% within the month. As of the time of writing, it has increased by 16.06%, trading at HKD 71.5 with a turnover of HKD 9.04 billion. On the news front, on September 8th, clinical data for HARMONi-2 was released at the WCLC annual meeting, with AKESO's PD-1xVEGF dual antibody Ivosiren achieving the primary clinical endpoint of PFS in a head-to-head comparison with a PD-L1(+)NSCLC 1L indication. Huafu Securities pointed out that lung cancer is just the beginning of Ivosiren's global clinical development, and the overseas value of Ivosiren is yet to be reassessed. Morgan Stanley released a research report stating that Ivosiren's HARMONi-2 data exceeded expectations, and adjusting the company's revenue model to reflect overseas income contributions, the company's loss forecast for this year was reduced by 30%, next year's loss forecast by 17%, and the profit forecast for 2026 was raised by 13%. JPMorgan Chase pointed out that considering the upward revision of AK112 sales forecasts, the bank correspondingly increased AKESO's sales forecast by over 40%.